TY - JOUR
T1 - Effectiveness of palbociclib with aromatase inhibitors for the treatment of advanced breast cancer in an exposure retrospective cohort study
T2 - implications for clinical practice
AU - Alves da Costa, Filipa
AU - Cardoso Borges, Fábio
AU - Ramos, Adriana
AU - Mayer, Alexandra
AU - Brito, Claudia
AU - Ramos, Catarina
AU - Bernardo, Catarina
AU - Cossito, Mariane
AU - Furtado, Cláudia
AU - Ferreira, Arlindo R.
AU - Martins-Branco, Diogo
AU - da Costa Miranda, Ana
AU - Lourenço, António
N1 - Funding Information:
The authors acknowledge the RON network that cooperated in providing up-to-date information on cases diagnosed and treated with the drug of interest. Participating institutions: Centro Hospitalar Universitário de São João, Centro Hospitalar Universitário Lisboa Norte, Centro Hospitalar Universitário do Algarve, Hospital de Braga, Centro Hospitalar e Universitário de Coimbra, Centro Hospitalar de Trás-os-Montes e Alto Douro, Centro Hospitalar do Funchal, Centro Hospitalar de Vila Nova de Gaia/Espinho, Instituto Português de Oncologia de Coimbra Francisco Gentil, Centro Hospitalar Lisboa Ocidental, Hospital Garcia de Orta, Centro Hospitalar Universitário Lisboa Central, Hospital Distrital de Santarém, Centro Hospitalar de Entre o Douro e Vouga, Hospital da Senhora da Oliveira Guimarães, Centro Hospitalar de Setúbal, Centro Hospitalar e Universitário do Porto, Centro Hospitalar Tondela Viseu, Instituto Português de Oncologia de Lisboa Francisco Gentil, Hospital do Espírito Santo de Évora, Centro Hospitalar Barreiro Montijo, Hospital Beatriz Ângelo, Hospital do Santo Espírito da Ilha Terceira, Hospital do Divino Espírito Santo de Ponta Delgada, Hospital Pedro Hispano, Hospital Litoral Alentejano, Centro Hospitalar do Médio Ave, Hospital Distrital Caldas da Rainha, Centro Hospitalar Médio Tejo, Hospital Santa Luzia de Elvas, Hospital José Joaquim Fernandes Beja, Centro Hospitalar Universitário da Cova da Beira, Centro Hospitalar do Baixo Vouga, Hospital Professor Doutor Fernando Fonseca, Centro Clínico Champalimaud, Hospitais CUF, Hospitais da Luz, Hospitais dos Lusíadas).
Publisher Copyright:
© 2023, The Author(s).
PY - 2023/6/29
Y1 - 2023/6/29
N2 - Background: New drugs for locally advanced or metastatic breast cancer have led to clinical benefits, aside with increasing costs to healthcare systems. The current financing model for health technology assessment (HTA) privileges real-world data. As part of the ongoing HTA, this study aimed to evaluate the effectiveness of palbociclib with aromatase inhibitors (AI) and compare it with the efficacy reported in PALOMA-2. Methods: A population-based retrospective exposure cohort study was conducted including all patients initiating treatment in Portugal with palbociclib under early access use and registered in the National Oncology Registry. The primary outcome was progression free survival (PFS). Secondary outcomes considered included time to palbociclib failure (TPF), overall survival (OS), time to next treatment (TTNT), and proportion of patients discontinuing treatment due to adverse events (AEs). The Kaplan–Meier method was used and median, 1- and 2-year survival rates were computed, with two-sided 95% confidence intervals (95%CI). STrengthening the Reporting of OBservational studies in Epidemiology (STROBE) guidelines for reporting observational studies were used. Results: There were 131 patients included. Median follow-up was 28.3 months (IQR: 22.7–35.2) and median duration of treatment was 17.5 months (IQR: 7.8–29.1). Median PFS was 19.5 months (95%CI 14.2–24.2), corresponding to a 1-year PFS rate of 67.9% (95%CI 59.2–75.2) and a 2-year PFS rate of 42.0% (95%CI 33.5–50.3). Sensitivity analysis showed median PFS would increase slightly when excluding those not initiating treatment with the recommended dose, raising to 19.8 months (95%CI 14.4–28.9). By considering only patients meeting PALOMA-2 criteria, we could observe a major difference in treatment outcomes, with a mean PFS of 28.8 months (95%CI 19.4–36.0). TPF was 19.8 months (95%CI 14.2–24.9). Median OS was not reached. Median TTNT was 22.5 months (95%CI 18.0–29.8). A total of 14 patients discontinued palbociclib because of AEs (10.7%). Conclusions: Data suggest palbociclib with AI to have an effectiveness of 28.8 months, when used in patients with overlapping characteristics to those used in PALOMA-2. However, when used outside of these eligibility criteria, namely in patients with less favorable prognosis (e.g., presence of visceral disease), the benefits are inferior, even though still favorable.
AB - Background: New drugs for locally advanced or metastatic breast cancer have led to clinical benefits, aside with increasing costs to healthcare systems. The current financing model for health technology assessment (HTA) privileges real-world data. As part of the ongoing HTA, this study aimed to evaluate the effectiveness of palbociclib with aromatase inhibitors (AI) and compare it with the efficacy reported in PALOMA-2. Methods: A population-based retrospective exposure cohort study was conducted including all patients initiating treatment in Portugal with palbociclib under early access use and registered in the National Oncology Registry. The primary outcome was progression free survival (PFS). Secondary outcomes considered included time to palbociclib failure (TPF), overall survival (OS), time to next treatment (TTNT), and proportion of patients discontinuing treatment due to adverse events (AEs). The Kaplan–Meier method was used and median, 1- and 2-year survival rates were computed, with two-sided 95% confidence intervals (95%CI). STrengthening the Reporting of OBservational studies in Epidemiology (STROBE) guidelines for reporting observational studies were used. Results: There were 131 patients included. Median follow-up was 28.3 months (IQR: 22.7–35.2) and median duration of treatment was 17.5 months (IQR: 7.8–29.1). Median PFS was 19.5 months (95%CI 14.2–24.2), corresponding to a 1-year PFS rate of 67.9% (95%CI 59.2–75.2) and a 2-year PFS rate of 42.0% (95%CI 33.5–50.3). Sensitivity analysis showed median PFS would increase slightly when excluding those not initiating treatment with the recommended dose, raising to 19.8 months (95%CI 14.4–28.9). By considering only patients meeting PALOMA-2 criteria, we could observe a major difference in treatment outcomes, with a mean PFS of 28.8 months (95%CI 19.4–36.0). TPF was 19.8 months (95%CI 14.2–24.9). Median OS was not reached. Median TTNT was 22.5 months (95%CI 18.0–29.8). A total of 14 patients discontinued palbociclib because of AEs (10.7%). Conclusions: Data suggest palbociclib with AI to have an effectiveness of 28.8 months, when used in patients with overlapping characteristics to those used in PALOMA-2. However, when used outside of these eligibility criteria, namely in patients with less favorable prognosis (e.g., presence of visceral disease), the benefits are inferior, even though still favorable.
KW - Cancer registry
KW - Effectiveness
KW - Palbociclib
KW - Safety
UR - http://www.scopus.com/inward/record.url?scp=85163767099&partnerID=8YFLogxK
U2 - 10.1186/s13058-023-01678-5
DO - 10.1186/s13058-023-01678-5
M3 - Article
C2 - 37386484
AN - SCOPUS:85163767099
SN - 1465-5411
VL - 25
JO - Breast Cancer Research
JF - Breast Cancer Research
IS - 1
M1 - 78
ER -